Form 4: Liquidia Corp CMO Reports Stock Vesting and Tax-Related Sale

Liquidia Corp's Chief Medical Officer, Rajeev Saggar, reported the vesting of performance stock units and a subsequent sale of shares to cover tax obligations, as detailed in a recent SEC Form 4 filing.

Summary

• Rajeev Saggar, Chief Medical Officer of Liquidia Corp (LQDA), reported transactions involving the company's common stock.
• On June 3, 2025, 17,654 Performance Stock Units (PSUs) vested and converted into common stock on a one-for-one basis.
• These PSUs were part of a grant of 56,492 PSUs on January 11, 2024, with vesting contingent on a time-based schedule and the first commercial sale of YUTREPIA.
• On June 4, 2025, Mr. Saggar sold 7,597 shares of common stock at a price of $16.97 per share.
• This sale was executed pursuant to a Rule 10b5-1 plan adopted on December 15, 2023, and was specifically to cover taxes associated with the settlement of the vested PSUs.
• Following these transactions, Mr. Saggar beneficially owns 273,209 shares of common stock directly.
• Additionally, Mr. Saggar holds 38,838 unvested PSUs and various tranches of unvested Restricted Stock Units (RSUs) totaling 152,981 shares from grants in 2022, 2023, 2024, and 2025, along with 6,291 shares acquired through the Employee Stock Purchase Plan.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While there was a sale of shares, it was a pre-planned transaction to cover tax liabilities from vested equity, which is a routine event. The vesting of PSUs is a positive indicator of executive compensation milestones being met.

Positives

• The vesting of 17,654 Performance Stock Units indicates that certain time-based and potentially performance-based conditions have been met, reflecting progress towards company goals or continued tenure of the executive.

Negatives

• The sale of 7,597 shares, even for tax purposes, reduces the direct beneficial ownership of the Chief Medical Officer in the company.

Future Outlook

The vesting of certain Performance Stock Units is contingent upon the first commercial sale of YUTREPIA by the Issuer, indicating a future milestone for the company's product.

Management Comments

• The transaction was effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on December 15, 2023, indicating pre-planned stock activity.
• The shares were sold to cover taxes associated with the settlement of PSUs that were initially granted to the Reporting Person on January 11, 2024.

Industry Context

This Form 4 filing details a routine insider transaction, specifically the vesting of equity awards and a subsequent sale to cover tax obligations, which is a common occurrence for executives receiving equity compensation in publicly traded companies within the pharmaceutical or biotechnology sector.

Corporate Governance

Stakeholder Impact

• Shareholders: The sale of shares by a Chief Medical Officer is a routine event for tax purposes and is unlikely to have a significant impact on shareholder sentiment or the company's operational outlook. The vesting of equity awards aligns executive incentives with shareholder value over time.

Next Steps

• Continued vesting of remaining unvested Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) according to their respective schedules.
• The first commercial sale of YUTREPIA, which is a condition for the full vesting of certain PSUs.

Key Dates

Keywords

Liquidia Corp, LQDA, Form 4, Insider Trading, Stock Ownership, Rajeev Saggar, Chief Medical Officer, Performance Stock Units, PSU, Restricted Stock Units, RSU, Stock Sale, Tax Obligation, Rule 10b5-1 Plan, YUTREPIA